GlobeNewswire
Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference
Polarean
11 min read

In This Article:

Polarean
Polarean

Featured Company at Respiratory Innovation Summit to Jump Start Robust Presence

DURHAM, NC and LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX),  a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, has been selected as one of the featured companies and a poster presenter at the American Thoracic Society’s (ATS) 2024 Respiratory Innovation Summit (RIS), a testament to the value of our XENOVIEW technology seen across lung clinicians and pulmonary drug developers. The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd. Visit booth #2813 to engage directly with our executive team, including Christopher von Jako, PhD, Chief Executive Officer; Alex Dusek, Chief Commercial Officer; and Kiarash Emami, PhD, VP of Technology & Applications. Discover firsthand how Polarean strives to revolutionize pulmonary medicine through direct visualization of lung ventilation as we share detailed insights, forge valuable connections, and collaborate to shape the future of lung imaging.

This year, the breadth of Xenon MRI research and the number of displays outpaced all previous years, with 33 presentations from 10 different sites and multiple categories, including asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, hematopoietic stem cell transplant, lung cancer resection, radiation-induced lung injury, pulmonary arterial hypertension, and thoracic insufficiency syndrome.   


Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships. These events provide an unparalleled opportunity to elevate awareness of our technology among clinicians, regulators, investors, and potential pharmaceutical industry partners. As we strive to advance our commercialization strategy, the increase in Xenon MRI posters and presentations marks significant strides in amplifying understanding and enthusiasm for Xenon MRI and the spectrum of therapeutic disciplines that could benefit from our technology.”

Terms and Privacy Policy
Your Privacy Choices
Utah Privacy Notice

Recommended Stories